JAK3i, or JAK3 inhibitor, is a small molecule designed to selectively inhibit Janus kinase 3 (JAK3), an enzyme involved in the signaling pathways of various cytokines and growth factors. This inhibition is particularly relevant in the context of immune responses and hematopoiesis. The chemical substance with the CAS number 1918238-72-8 is characterized by its ability to modulate immune system activity, making it a potential therapeutic agent for autoimmune diseases and certain hematological conditions. JAK3i exhibits specificity for JAK3 over other JAK family members, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. The compound's pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are essential for determining its clinical utility. Additionally, ongoing research is focused on its safety profile and potential side effects, as with any pharmacological agent. Overall, JAK3i represents a promising avenue in targeted therapies aimed at modulating immune responses.

JAK3i is a selective covalent inhibitor of JAK3 kinase activity. It reveals two distinct temporal waves of STAT5 phosphorylation and more potently targets the second wave, which is required for cell cycle progression and T cell proliferation.

JAK3i

(JAK3 inhibitor JAK3i)

1918238-72-8: JAK3i, or JAK3 inhibitor, is a small molecule designed to selectively inhibit Janus kinase 3 (JAK3), an enzyme involved in the signaling pathways of various cytokines and growth factors. This inhibition is particularly relevant in the context of immune responses and hematopoiesis. The chemical substance with the CAS number 1918238-72-8 is characterized by its ability to modulate immune system activity, making it a potential therapeutic agent for autoimmune diseases and certain hematological conditions. JAK3i exhibits specificity for JAK3 over other JAK family members, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. The compound's pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are essential for determining its clinical utility. Additionally, ongoing research is focused on its safety profile and potential side effects, as with any pharmacological agent. Overall, JAK3i represents a promising avenue in targeted therapies aimed at modulating immune responses.

JAK3i

<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>

CAS 1918238-72-8

JAK3i (JAK3 inhibitor JAK3i)

JAK3i

Ref: 54-BUP07340

JAK3i

Ref: TM-T27650